Hikal Ltd Stock Falls to 52-Week Low of Rs.169.1 Amidst Continued Downtrend

Recent Price Movement and Market Context

On 16 Mar 2026, Hikal Ltd’s stock recorded a day change of -1.62%, underperforming its Pharmaceuticals & Biotechnology sector by 1.05%. The stock has been on a losing streak for two consecutive sessions, delivering a cumulative return of -5.35% over this period. This decline has pushed the share price below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling sustained bearish momentum.

In contrast, the broader market showed resilience with the Sensex recovering from an initial negative opening to close 0.18% higher at 74,698.77. However, the Sensex itself remains 4.38% above its own 52-week low of 71,425.01 and is trading below its 50-day moving average, reflecting a cautious market environment. Mega-cap stocks led the market gains, while smaller-cap stocks like Hikal faced continued pressure.

Financial Performance and Valuation Metrics

Hikal Ltd’s financial performance over the past year has been subdued, with the stock delivering a negative return of -55.59%, significantly lagging the Sensex’s positive 1.18% return over the same period. The stock’s 52-week high was Rs.456.6, highlighting the extent of the decline.

The company’s long-term fundamentals have shown weakness, with a compounded annual growth rate (CAGR) of operating profits declining by -16.94% over the last five years. This deterioration in profitability is further reflected in the company’s average Return on Equity (ROE) of 8.00%, indicating modest returns on shareholders’ funds.

Debt servicing capacity remains a concern, with a Debt to EBITDA ratio of 2.51 times, suggesting elevated leverage relative to earnings before interest, taxes, depreciation, and amortisation. The company’s Return on Capital Employed (ROCE) for the half-year ended December 2025 was notably low at 4.44%, underscoring limited efficiency in capital utilisation.

Profitability and Comparative Valuation

Profitability metrics have shown a marked decline, with profits falling by 66.4% over the past year. Despite this, the company’s valuation metrics suggest an attractive entry point relative to peers. The Enterprise Value to Capital Employed ratio stands at 1.5, indicating that the stock is trading at a discount compared to the average historical valuations of its sector counterparts.

However, the company’s performance has been below par not only in the recent term but also over the longer horizon. Hikal has underperformed the BSE500 index across the last three years, one year, and three months, reflecting persistent challenges in maintaining competitive growth and returns.

Shareholding and Market Sentiment

The majority shareholding remains with the company’s promoters, maintaining a stable ownership structure. Despite this, the stock’s Mojo Score has deteriorated to 23.0, with a Mojo Grade of Strong Sell as of 14 Nov 2025, downgraded from a previous Sell rating. This grading reflects the market’s assessment of the company’s weak long-term fundamentals and subdued growth prospects.

Technical Indicators Signal Continued Pressure

Technical analysis corroborates the bearish outlook, with multiple indicators pointing to negative momentum. The Moving Average Convergence Divergence (MACD) is bearish on both weekly and monthly charts. Bollinger Bands also indicate bearish trends across these timeframes. The daily moving averages remain firmly bearish, while the KST (Know Sure Thing) indicator aligns with this negative sentiment on weekly and monthly scales.

Dow Theory assessments show a mildly bearish stance on both weekly and monthly charts. The On-Balance Volume (OBV) indicator is mildly bearish weekly, with no clear trend monthly, suggesting subdued buying interest. The Relative Strength Index (RSI) does not currently signal any oversold or overbought conditions, indicating the stock is trading in a neutral momentum zone despite the downtrend.

Summary of Key Metrics

To summarise, Hikal Ltd’s stock has reached a new 52-week low of Rs.169.1, reflecting a significant decline from its 52-week high of Rs.456.6. The stock’s performance over the past year has been notably weak, with returns of -55.59% and a steep drop in profits by 66.4%. The company’s financial ratios, including a Debt to EBITDA ratio of 2.51 and a ROCE of 4.44%, highlight ongoing challenges in profitability and capital efficiency.

Technical indicators consistently signal bearish momentum, and the stock trades below all major moving averages. The Mojo Grade of Strong Sell further underscores the cautious stance on the stock’s outlook based on current fundamentals and market conditions.

Market Environment and Sectoral Comparison

While the broader Sensex index has shown resilience, led by mega-cap stocks, smaller-cap stocks such as Hikal continue to face headwinds. The Pharmaceuticals & Biotechnology sector has experienced mixed performance, with Hikal’s valuation discount relative to peers suggesting a divergence from sector averages. This discount is partly attributable to the company’s subdued growth and profitability metrics compared to sector norms.

Concluding Observations

Hikal Ltd’s stock performance and financial indicators reflect a period of sustained pressure, with the share price touching a 52-week low amid weak earnings growth and elevated leverage. The technical and fundamental data collectively point to a challenging environment for the company, with valuation metrics indicating a discount relative to peers but accompanied by ongoing concerns regarding profitability and capital returns.

Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today